KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Preferred Shares (2016 - 2018)

Historic Preferred Shares for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Q3 2018 value amounting to $3.8 billion.

  • Teva Pharmaceutical Industries' Preferred Shares rose 566.3% to $3.8 billion in Q3 2018 from the same period last year, while for Sep 2018 it was $3.8 billion, marking a year-over-year increase of 566.3%. This contributed to the annual value of $3.6 billion for FY2017, which is 30.39% up from last year.
  • Teva Pharmaceutical Industries' Preferred Shares amounted to $3.8 billion in Q3 2018, which was up 566.3% from $3.8 billion recorded in Q2 2018.
  • Teva Pharmaceutical Industries' 5-year Preferred Shares high stood at $3.8 billion for Q3 2018, and its period low was $3.3 billion during Q4 2015.
  • Moreover, its 4-year median value for Preferred Shares was $3.6 billion (2016), whereas its average is $3.6 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Preferred Shares skyrocketed by 999.7% in 2016 and then changed by 0.0% in 2017.
  • Teva Pharmaceutical Industries' Preferred Shares (Quarter) stood at $3.3 billion in 2015, then rose by 10.0% to $3.6 billion in 2016, then increased by 0.3% to $3.6 billion in 2017, then grew by 5.34% to $3.8 billion in 2018.
  • Its Preferred Shares was $3.8 billion in Q3 2018, compared to $3.8 billion in Q2 2018 and $3.7 billion in Q1 2018.